Investor Due Diligence Template: Evaluating Life-Science Startups’ First Commercial Product

Hook: Why your next life‑science investment needs a specialized due diligence playbook

Investors sour on life‑science deals not because the science is weak, but because commercial execution — reimbursement, regulatory clarity, manufacturing scale and real revenue pathways — is the hardest part. If you’re evaluating a company like Profusa launching its first product (their Lumee biosensor began commercial shipments in late 2025), a standard tech or SaaS DD checklist will miss the critical risk vectors that determine whether early revenue becomes sustainable growth.

This article gives a ready‑to‑use Investor Due Diligence Template tailored to life‑science startups launching their first commercial product in 2026. It focuses on the five deal breakers investors must evaluate: regulatory status, reimbursement pathways, clinical evidence, manufacturing readiness and revenue models. It also includes a scoring rubric, document request list, interview playbook for management and KPIs to track post‑close.

Inverted pyramid summary: What matters most, now

• Regulatory clarity: Does the product have an applicable clearance/approval or a credible path to it (PMA, De Novo, 510(k), CE, or other jurisdictions)? Are post‑market requirements and timelines understood?
• Reimbursement and coding: Are there existing CPT/HCPCS/Coverage pathways, or is Coverage with Evidence Development (CED) likely? What is the Medicare/LCD risk?
• Clinical evidence: Does evidence support the intended claims and prospective payer/value conversations? Is there RWE strategy to close evidence gaps?
• Manufacturing & supply chain: Is the product manufacturable at scale with predictable COGS, quality systems, and supplier controls?
• Revenue model & go‑to‑market: Can the company convert early adopters into repeatable sales with realistic assumptions on adoption curve, pricing and channel economics?

2026 landscape context — why this template is timely

Late 2025 and early 2026 accelerated several trends that change diligence priorities:

• RWE is mainstream: Regulators and payers increasingly accept Real‑World Evidence for label expansion and reimbursement decisions; expect RWE plans to be integral to commercialization strategies.
• Outcomes‑based contracting grows: Payers are more willing to pilot value‑based contracts for diagnostics and digital‑enabled devices, shifting commercial risk to manufacturers.
• Manufacturing resiliency: Onshoring and dual‑sourcing remain priorities; investors demand evidence of validated scale‑up and supplier risk mitigation.
• Regulatory complexity for AI and combination products: The EU AI Act and tighter combo product rules mean devices with software or biologic components need more layered regulatory planning.
• Selective capital: 2025‑26 investor appetite favors companies with clear early revenue and defensible margin paths — not just promising science.

How to use this template

Apply this template in three stages:

1. Pre‑read: Document request and red flag scan (1–2 days).
2. Deep diligence: Regulatory, clinical, manufacturing and commercial deep dives (2–4 weeks).
3. Integration readiness: Post‑term sheet operational plan and KPIs (30‑90 days pre‑close).

Due Diligence Template — Section by section

1) Regulatory status (score 0–3)

Focus questions:

• What regulatory pathway was used (PMA/510(k)/De Novo/CE/other)? Is the product cleared for the intended clinical use or only for research use/limited market?
• Are there active post‑market commitments, conditions of approval, or recalls?
• Does the company have a documented regulatory strategy for additional indications, claims, or geographies?
• Is software/AI in the product? If yes, is it classified under SaMD guidance and are cybersecurity requirements addressed?

Documents to request:

• Regulatory submission dossiers, FDA correspondence, 510(k)/PMA/De Novo decision letters or CE technical documentation
• Post‑market commitments and surveillance plans
• Quality agreements with notified bodies, if applicable
• Risk management (ISO 14971) and clinical evaluation reports (MDR/IVDR‑style)

Red flags:

• Ambiguous claim language that prevents payer alignment
• Pending major corrective actions or unresolved FDA observations
• No compliance with AI/ML lifecycle or cybersecurity guidance if applicable

2) Reimbursement & coding (score 0–3)

Focus questions:

• Is there an established CPT/HCPCS code or does the company rely on unlisted codes or CPT proprietary add‑ons?
• Has the company engaged with CMS for national coverage, or is it building local coverage via LCDs and private payers?
• Is a Coverage with Evidence Development (CED) pathway appropriate or already in progress?
• What are realistic net price assumptions after discounts, bundling and value‑based rebates?

Documents to request:

• Payer letters of intent, early adoption contracts, reimbursement submissions and economic models
• Coding requests, existing CPT/HCPCS applications, and fee schedules used in pilots
• Health economic models (cost‑effectiveness, budget impact, and value dossiers)

Red flags:

• No explicit payer conversations or reliance on out‑of‑pocket consumer purchasing for clinical use
• Overoptimistic pricing without payer evidence
• Assumptions that Medicare will automatically cover without credible historical precedents

3) Clinical evidence & adoption risk (score 0–3)

Focus questions:

• Do the clinical endpoints align with how payers and clinicians make decisions (hard endpoints vs surrogate metrics)?
• Are study populations representative of target payer populations (age, comorbidity, settings)?
• Is RWE collection planned to support label expansion or reimbursement (claims linkage, registries)?
• Who are the KOLs and early adopter sites, and are there reproducible protocols for adoption?

Documents to request:

• Full clinical study reports, protocols, statistical analysis plans and IRB approvals
• RWE strategy documents, data sharing agreements and pilot site data
• Adoption playbook, training materials and reimbursement scripts for clinicians

Red flags:

• Single‑site efficacy only with no multicenter reproducibility
• Endpoints that don’t translate to payer economics
• Absence of a plan to collect payer‑grade RWE within 12–24 months

4) Manufacturing readiness & quality systems (score 0–3)

Focus questions:

• Is manufacturing in‑house or outsourced? Are CMOs audited and qualified?
• Are manufacturing processes validated, with clear yield, cycle time, and COGS projections?
• Are supply chain risks identified and mitigated (single supplier, rare materials, import/export constraints)?
• Does the company have documented lot release criteria, stability data and packaging validation?

Documents to request:

• Supplier agreements, audit reports, CAPA logs and change control history
• Process validation reports, equipment qualification documents and batch records
• Cost model for COGS including materials, labor, yield loss and overhead

Red flags:

• No audited backup suppliers for critical components
• Inadequate environmental/sterility control where applicable
• Unrealistic yield or COGS assumptions without validation batches

5) Commercial & revenue pathways (score 0–3)

Focus questions:

• What channels will the company use (direct sales, lab partnerships, distributors, OEM)?
• What is the customer acquisition cost (CAC) and payback period on early revenue?
• What is the anticipated payer mix (Medicare, commercial, self‑pay) and impact on realized pricing?
• Is there a credible ramp plan, including staffing, logistics, and service operations?

Documents to request:

• Sales forecasts, CAC analysis, churn and retention metrics from pilots
• Channel agreements, distribution terms, and customer contracts
• Go‑to‑market plan with hiring timelines and unit economics

Red flags:

• Sales estimates that ignore channel margins or installation/service costs
• No plan to convert pilots into recurring revenue
• Pricing that requires payers to change standard of care without clear evidence

Scoring rubric and decision thresholds

Score each of the five categories 0 (fatal flaw) to 3 (low risk). Aggregate score guides action:

• 12–15: Green — proceed to term sheet with standard reps and one or two performance milestones.
• 8–11: Yellow — pursue with conditional terms, require remediation plan and milestone‑based tranches.
• 0–7: Red — high risk; consider pass or deeply discounted deal with strong protective provisions.

Operational due diligence: checklists and templates

Quick Document Checklist (pre‑read)

• Regulatory decision letters and correspondence
• Clinical study reports and protocols
• Quality management system (QMS) certificates and audit reports
• Manufacturing process and validation reports
• Payer engagement materials and economic models
• Cap table, outstanding warrants, and option pool details
• Top 10 supplier contracts and supply chain risk register

Interview playbook — whom to ask and what to probe

• CEO/Founder: strategy for adoption, runway, and next regulatory milestones.
• Chief Medical Officer: clinical evidence gaps and RWE plans.
• Head of Regulatory Affairs: timelines for claims, outstanding issues with regulators and global expansion plan.
• Head of Manufacturing/Operations: demonstrated scale, yield assumptions, and CMO stacks.
• Head of Commercial: pilot KPIs, CAC, payer conversations and channel economics.

Financial modeling inputs specific to first‑product life‑science launches

Use scenario modeling (conservative, base, aggressive). Key inputs to stress:

• Realizable price = list price * expected payer discount (include payer mix)
• Adoption curve = time to convert pilot sites + adoption multiplier per year
• COGS per unit = materials + direct labor + packaging + warranty/service costs
• SKU and inventory assumptions = minimum order quantities, shelf life and obsolescence
• Sales & marketing ramp = reps per territory, ramp time, productivity and training cost

Stress test with:

• Delayed reimbursement timeline (add 12–24 months)
• Lower-than‑expected yield (increase COGS by 20–40%)
• Higher CAC or slower conversion rates

Case example: Applying the template to a company like Profusa launching Lumee

Profusa’s Lumee sensor began commercial shipments in late 2025; the first revenue matters more than ever. Here’s how an investor would apply the template:

• Regulatory: Confirm the market authorization and check for any post‑market studies required. If the device had conditional research‑use only authorizations in some markets, escalate to red flag.
• Reimbursement: For tissue oxygen biosensors, investigate whether CPT codes exist for the clinical context and whether studies show impact on hospital LOS or readmissions (which payers value).
• Clinical evidence: Examine multicenter reproducibility and whether Lumee’s endpoints translate into payer‑relevant health economics (e.g., fewer complications, faster discharge).
• Manufacturing: Validate the CMO’s capability to meet device tolerances and batch records, and confirm material suppliers aren’t single‑point failures.
• Revenue pathway: Ensure pilots demonstrate repeat purchases and that the company has a clear pricing script and contracting approach for hospitals and research customers.

Advanced strategies investors should require in 2026

• RWE commitment clause: Require a covenant that the company enrolls X patients into RWE registries within Y months. Tie funding tranches to evidence milestones that unlock higher reimbursement potential.
• Manufacturing ramp milestones: Fund scale‑up contingent on successful validation batches and second supplier qualification.
• Outcomes contract playbook: Ensure management has pre‑negotiated terms for pilot value‑based contracts that limit downside and share upside with payers.
• Regulatory hedges: Include reps about freedom to operate and indemnities around pending regulatory actions; require escrow of clinical/technical IP if appropriate.

KPIs to monitor after investment

• Time to first repeat order (target: < 90 days from first delivery)
• Gross margin per unit and quarter‑on‑quarter improvement
• Number of patients enrolled in RWE/registries per quarter
• Percentage of revenue under contract vs spot purchases
• Manufacturing yield and on‑time delivery rate

Investor takeaway: In 2026, life‑science investments hinge less on the novelty of the science and more on the defensibility of the commercialization path — regulators, payers and manufacturers now shape valuation more than ever.

Red flags that should trigger deal pause or heavy indemnities

• Regulatory approvals that are limited to research use in target markets without a clear path to clinical labeling
• No credible payer engagement or evidence to support reimbursement claims
• Manufacturing dependent on a single unvetted supplier for critical components
• Clinical evidence based on surrogate endpoints without linkage to outcomes payers care about

Ready‑to‑use investor checklist (printable)

1. Obtain regulatory decision letters and confirm active status.
2. Review full clinical study reports and check reproducibility across sites.
3. Audit CMO(s) or supplier QC reports; request sample batch records.
4. Validate reimbursement pathway and request payer LOIs or pilot contracts.
5. Run three financial scenarios stressing reimbursement delays and COGS shocks.
6. Insert RWE and manufacturing milestones into the term sheet with defined acceptance criteria.

Final checklist — negotiation language to protect investors

• Milestone‑based tranche release tied to: (a) validated manufacturing batch yield, (b) X patients in RWE registry, (c) signed contract with at least one payer or hospital network.
• Price protection if COGS exceed threshold before Series A close.
• Information rights on quality events, regulatory inquiries and supplier failures.
• Escrow or escrow‑like protections for critical IP or device master files until regulatory risks abate.

Concluding action plan — 30/60/90 days

1. 30 days: Complete doc review, regulatory and payer initial calls, and preliminary scoring.
2. 60 days: Conduct site audits, finalize clinical evidence assessment and negotiate milestone‑based terms.
3. 90 days: Close with operational playbook in place; begin monitoring the KPIs and RWE enrollment.

Closing: Make your investment conditional on commercial defensibility

Life‑science startups launching their first product enter an unforgiving commercial market. A company can have a brilliant sensor (as Profusa has demonstrated) and still fail to scale without payer alignment, manufacturing muscle and an evidence plan that convinces adoption gatekeepers. Use this template to move beyond scientific promise to commercial reality — structure deals that reward validated revenue milestones and protect you from the common failure modes investors face in 2026.

Next steps: Download the full, editable DD spreadsheet and checklist to run this template on your next life‑science opportunity, or contact our investor diligence team to run a white‑glove assessment of your pipeline company.

Related Reading

• Why 2025’s Surprising Economic Strength Matters to Creators — And Why 2026 Could Be Better
• Brass Spotlight: How to Start a Trombone Culture in Tamil Nadu Schools
• How to Flip TCG Deals Safely: A Beginner’s Guide to Reselling Discounted ETBs
• Games Should Never Die: Industry Response to New World's Shutdown and What Comes Next
• Storyboard Strategies for Long-Running Franchises: Avoiding Fatigue in Established IP